Answers are grounded in this paper and cite their sources.
CAR-T cells have made dramatic inroads in targeting CD19-positive B-cell malignancies. This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia.
No takes yet. Share an insight, caveat, or question.
Leick et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: